Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-2493

ABSTRACT: Transcription profiling by array of human HEK293-M2 cells to identify human ORFs conferring resistance to various drug treatments

PROVIDER: E-MTAB-2493 | ExpressionAtlas | 2015-07-13

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-2493-analysis-methods.tsv	Tabular
	E-MTAB-2493-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-2493-configuration.xml	Xml
	E-MTAB-2493-percentile-ranks.tsv	Tabular
	E-MTAB-2493.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 48

Similar Datasets

293_hORF3.1_drug_treatments

Project description:Identification of human ORFs conferring resistance to various drug treatments when overexpressed into HEK293-M2, assessed by microarrays

2014-05-15 | E-MTAB-2493 | biostudies-arrayexpress

GNPS - Metabolomics Integration with Gene expression profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC large B cell Lymphoma

Project description:Drug resistant acute B-cell lymphoma cells were analyzed via LC-MS metabolomics to identify deregulated metabolic pathways that are associated with drug resistance.

2021-03-16 | MSV000087059 | GNPS

RNA sequencing of ADIPOR2 knockout HEK293 cells undergone various treatments with palmitic acid

Project description:RNA sequencing of ADIPOR2 knockout HEK293 cells undergone various treatments with palmitic acid

| PRJNA666670 | ENA

Expression data from MCF7 and MCF7-LTED cells treated with YC-1

Project description:To identify novel therapeutic opportunities for patients with acquired resistance to endocrine treatments in breast cancer, we applied a high-throughput drug screen. The IC50 values were determined for MCF7 and MCF7-LTED cells.

2014-03-17 | GSE38829 | GEO

Differential gene expression profiles of side population and non-side population cells of malignant pleural mesothelioma

Project description:Malignant pleural mesothelioma (MPM), which is associated with occupational asbestos exposure, is a deadly disease with no effective treatments due mainly to its high resistance to anti-cancer drugs. The molecular mechanisms responsible for its chemotherapeutic resistance are complicated and undefined. However, the presence of side population cells (SP cells) in tumors is a well-accepted explanation for their anti-cancer drug resistance. To identify SP cell-specific gene expression signature, microarray technique has been employed. Our data show differential gene expression profiles between SP and non-SP cells of H2714 mesothelioma cells. SP cells over-expressed genes associated with cancer stem cell (CSC) and drug resistance: DUSP6, SPRY2 and IL6, as well as multi-pathways, including the cancer stem cell-associated pathways Notch and c-Kit. Therefore, we believe that targeting CSC-specific genes and pathways in SP cells may hold the key to the discovery of effective treatments for reversing chemotherapeutic resistance to MPM treatment. 4 samples

2011-11-18 | E-GEOD-33734 | biostudies-arrayexpress

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells [ATAC-seq]

Project description:Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. Whilst patients treated with osimertinib show clinical benefit, disease progression and drug resistance are common. Emergence of de novo acquired resistance from a drug tolerant persister (DTP) cell population is one mechanism proposed to explain progression on osimertinib and other targeted cancer therapies. Here we profiled osimertinib DTPs using RNA-seq, ChIP-seq, and ATAC-seq to characterize the features of these cells and performed drug screens to identify therapeutic opportunities.

2022-04-06 | GSE193256 | GEO

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells [RNA-seq]

2022-04-06 | GSE193258 | GEO

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells [ChIP-seq]

2022-04-06 | GSE193257 | GEO

Differential gene expression profiles of side population and non-side population cells of malignant pleural mesothelioma

2011-11-18 | GSE33734 | GEO

Expression data from mesothelial (LP9) and mesothelioma cells (HMESO) inhibited for extracellular-regulated kinase (ERK) 1, 2, or 5

Project description:Extracellular-regulated kinases (ERK1/2 and 5) are known to play important roles in growth and drug resistance of various cancers. Here we show roles of inhibition of ERK1, ERK2, or ERK5 on gene expression profiles of epithelioid malignant mesothelioma (MM) cells (HMESO). Untransfected human mesothelial cells (LP9), MM cells (HMESO) or HMESO cells stably transfected with shControl, shERK1, shERK2 , or shERK5 plasmids were used. Microarrays were performed on samples from 3 independent experiments. Each sample was analyzed on a separate array (3 independent biological replicates).

2010-05-08 | E-GEOD-21750 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data